WHO Warns Obesity Drugs Will Remain Inaccessible to Most Who Need Them

The World Health Organization (WHO) has issued its first global guidance for using a new class of weight-loss medicines. This move addresses a growing health crisis, as obesity now affects over one billion people worldwide. The guidelines focus on drugs known as GLP-1 receptor agonists, like semaglutide. These medications help manage weight but are expensive and often in short supply. Experts analyzing the situation predict a severe access gap. They estimate these drugs will reach fewer than 10% of the people who medically need them. Global obesity rates are expected to double by 2030. The WHO guidance aims to help doctors use these drugs correctly where they are available, while countries seek longer-term solutions.